{ "slug": "menopause-hormone-symptoms", "round": 2, "group": 7, "date": "2026-10-14", "authoring_model": "Sol 6.1", "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)", "canonical_path": "hsef_v53_traffic_first_five_2026-10-12/menopause-hormone-symptoms/menopause-hormone-symptoms.review.md", "level_before": "Ζ", "level_after": "Ζ", "confidence_before": "High", "confidence_after": "High", "role_before": "reinforcing / stabilizing factor", "role_after": "reinforcing / stabilizing factor", "pmids_checked": 68, "pmids_failed": 0, "retractions_or_eoc_found": 0, "errata_attached": 5, "claims_spot_checked": 15, "validator": { "before": "FAIL — 1 fail, 0 warn, 32 pass (v5.lay_summary)", "after": "FAIL — 1 fail, 0 warn, 32 pass (v5.lay_summary)", "note": "Validator 2.4 enforces the v5.4 lay-summary requirement against a v5.3 package; unchanged by this pass and not a defect in the review." }, "findings": [ { "id": "AR-1", "severity": "Major", "type": "momentum_boilerplate", "location": [ "AT A GLANCE table", "Final score, causal direction and M/S/D", "scorecard extended_scoring_MSD.momentum" ], "original": "Decisive work underway", "corrected": "Mechanistic only", "evidence": "The framework defines 'Decisive work underway' as someone running an experiment that could cross the next threshold, with a required naming artifact. The only named artifact, OASIS-3 (PMID 40920404), is a completed phase 3 elinzanetant trial bearing on the rank-2 nonhormonal rival model, not on SC2's stated Eta requirement (mediator isolation plus prospective cross-context control). The review's own Stability entry states the raising triggers are proposed rather than ongoing, contradicting the Momentum value.", "level_impact": "none (M/S/D modify no letter)" }, { "id": "AR-2", "severity": "Minor", "type": "rendering_defect", "location": [ "evidence card [22] (PMID 16932240)", "evidence card [26] (PMID 16735935)", "matching scorecard ledger rows" ], "original": "ErratumIn: PMIDnot supplied.", "corrected": "ErratumIn: PMID not supplied.", "evidence": "Reference-builder missing space. Verified against the retrieval record that PubMed supplies no erratum PMID for either parent, so the flag content was correct and only the rendering was wrong." }, { "id": "AR-3", "severity": "Editorial", "type": "rendering_defect", "location": [ "PROPOSED DECISIVE EXPERIMENTS readout/controls line" ], "original": "composites.. / exclusions.. / prevention.. / unestablished..", "corrected": "single sentence terminators", "evidence": "Field-concatenation artefact; no change of meaning." }, { "id": "AR-4", "severity": "Major", "type": "renderer_defect_nominal_as_rival", "location": [ "AT A GLANCE, Best-supported rival line" ], "original": "Sex-steroid replacement reduces hormone-withdrawal symptoms (the nominal, tournament rank 1)", "corrected": "Nonhormonal thermoregulatory pathway modulation (rank 2), with a clause noting the nominal ranks first and so is not its own rival", "evidence": "Renderer defect: the \"Best-supported rival\" line is generated from `competing_models.models_evaluated[0]`, which here carries `is_nominal: true` and rank 1, so the prose named the nominal as its own rival. Prose-only; the tournament, the level and Rule 9 are untouched." }, { "id": "AR-5", "severity": "Minor", "type": "confidence_rationale", "location": [ "scorecard final_score.confidence_rationale" ], "original": "density, heterogeneous controls and incomplete access set the confidence, not correctness.", "corrected": "evidence density, independent replication and heterogeneity of controls set the confidence; access depth and belief in correctness do not.", "evidence": "The framework ties confidence to evidence density and reproducibility; the boilerplate rationale named \"incomplete access\" as a determinant. Rewritten to rest on density, replication and heterogeneity. Band re-tested against both band texts and unchanged. High is correct here: placebo-controlled hormone trials for vasomotor symptoms run across many independent groups, routes, countries and decades." } ], "rejected_findings": [ { "id": "RJ-1", "claim": "SC2's Zeta rests on two lines sharing systemic-estrogen pharmacology, so the headline should be Epsilon.", "resolution": "Rejected. The framework credits a mechanism-derived prediction tested by an instrument unrelated to the one that generated the mechanism; the sweating-threshold and skin-conductance work (PMIDs 11872200, 10411797, 15772562) is instrumentally unrelated to the symptom diary. Framework text does not force a change. Most contestable judgement in the review." }, { "id": "RJ-2", "claim": "Six reference years differ from PubMed by one.", "resolution": "Rejected per the print-versus-e-pub convention (refs 4, 28, 29, 32, 33, 34)." }, { "id": "RJ-3", "claim": "Fused PMID labels in prose are a missing-space rendering defect.", "resolution": "Rejected as consistent house style, distinct from the 'randomize3808' class." }, { "id": "RJ-4", "claim": "Collective-author leading-comma defect, empty DOI fields, or retrieval handles present.", "resolution": "Rejected; screened and none present. All 64 ledger rows carry PMID and DOI." }, { "id": "RJ-5", "claim": "Aggregation misapplied (scope-matched misread or an Epsilon subclaim setting the headline).", "resolution": "Rejected. Primary-subclaim pre-registered, SC2 named, alternatives reported (weakest-link Beta, scope-matched Zeta); arithmetic and derivation wording correct." }, { "id": "RJ-6", "claim": "Routing a menopause treatment claim through the metabolism/aging rubric is a scoring error.", "resolution": "Rejected. The adaptation is declared prospectively, literal criteria are quoted unchanged, and the substitution is stated, which is the framework's prescribed response to a rubric gap." }, { "id": "RJ-8", "claim": "Lead-reported artifacts: false approval boilerplate, reviewer-notes contradiction, confidence band wrong.", "resolution": "Screened. The first two do not apply (this is not a revised edition and no provenance clause of that kind is present). The band was re-tested against both framework band texts and High stands." } ], "benefit_risk_audit": { "numeric_effect_sizes_in_prose": 0, "absolute_vs_relative_errors": 0, "population_or_direction_errors": 0, "checked": [ "12771112 WHIMS dementia increase in women enrolled at 65 or older", "15213206 WHIMS CEE-alone no prevention", "18987368 APHRODITE 300 vs 150 micrograms, four breast cancers", "16735935 satisfying-event endpoint not significant", "16932240 INTIMATE NM1 improvements with SHBG-restricted analysis", "24861828 MsFLASH imprecise active-active difference", "27028912 ELITE CIMT only, no coronary CT difference", "27421538 ELITE cognition null", "26035291 KEEPS cognition null, oral CEE mood only", "29889748 REPLENISH dose-specific, bounded endometrial population", "24281237 muscle gains in the 25 mg supraphysiologic arm only", "25430996 testosterone cognition null across domains", "24716847 verbal-learning only, wellbeing null", "23545794 induced hypogonadism, depressive symptoms rare", "17626056 WISDOM harms when started years after menopause" ] }, "propagation_strings_for_lead": [ { "file_class": "package-level (OVERVIEW.md, READER.html, EDITORIAL_HANDOFF.md, BATCH_COMPLETION.json)", "old": "Decisive work underway", "new": "Mechanistic only", "scope": "the menopause-hormone-symptoms momentum field only" }, { "file_class": "package-level (OVERVIEW.md, READER.html, EDITORIAL_HANDOFF.md)", "old": "Best-supported rival: Sex-steroid replacement reduces hormone-withdrawal symptoms", "new": "Best-supported rival: Nonhormonal thermoregulatory pathway modulation (rank 2)", "scope": "the menopause-hormone-symptoms best-supported-rival field only" } ], "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14.", "findings_major": 2, "findings_minor": 2, "findings_editorial": 1, "rejected_count": 8, "lead_reported_artifacts_checked": [ "false approval boilerplate (revised editions only)", "confidence band set from access depth", "renderer bug printing the nominal as best-supported rival", "reviewer-notes / provenance contradiction" ], "lead_policy_confidence_band": { "recorded": "2026-10-14, lead adjudication", "step_1": "Strike access depth as a confidence determinant everywhere; it is neither evidence density nor reproducibility and never justifies a band.", "step_2": "Re-derive the band from what remains. Raise it only if access depth was the sole reason holding it down and the cited evidence meets the High text. Substantive evidence-quality or reproducibility concerns documented in the review (indirect effects, incomplete washout, residual confounding of the mechanism, reporter rather than endogenous readouts) are valid determinants and the band stands.", "principle": "A reviewer's uncertainty about the evidence is a legitimate reason for Moderate; a reviewer's uncertainty about their own reading access is not.", "precedents": "hiv-aids raised Moderate to High (invalid reason and nothing else); 3d-genome-regulation stays Moderate (real scientific reservations recorded in its own text). The two are consistent.", "reviewer_position": "Agreed; this is the distinction applied in this pass.", "applied_here": "Step 1 applied (rationale rewritten under AR-5). Step 2: band stands at High, which it already was; placebo-controlled hormone trials for vasomotor symptoms span many independent groups, routes, countries and decades, meeting the High text." } }